In the research of antiviral drugs, he presided over the international cooperation project of China-Spain government of the Ministry of Science and Technology "Synthesis of sulfur-containing heterocyclic compounds and their biological activities" (January 1997-December 1999) and "Synthesis of new anthraquinone ketone compounds and their antiviral and antitumor activities" (January 22-December 24); Presided over the key international cooperation project of the Ministry of Science and Technology "Research on New Non-nucleoside HIV Reverse Transcriptase Inhibitors" (33DF33, 23.1-26.12.5 million); He is in charge of the National Natural Fund "Research on Novel Non-nucleoside HIV Reverse Transcriptase Inhibitors of Thiothiazidine" (3371686, January 24-December 26) and "Design, Synthesis and Activity Study of Substituted Thiadiazine HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors" (3873133; 29.1-211.12), "Design, synthesis and activity study of pyrrolotriazine HIV-1 non-nucleoside reverse transcriptase inhibitors" (3772629, 28.1-21.12), "Research on non-equivalent double-target inhibitors targeting HIV-1 multi-target protein gp12" (National Natural Fund of China-cooperation between overseas and Hong Kong and Macao scholars In addition, he presided over projects such as Shandong Natural Fund; In the research of cardiovascular and cerebrovascular drugs, he has presided over the national major scientific and technological project of new drug creation, the candidate drug "Study on Ligustrazine Ferulide for Cardiovascular and Cerebrovascular Diseases" (29ZX913-117, Ministry of Science and Technology, January 29-January 212) and the Shandong Science and Technology Development Plan Project (26 GG 22263, January 27-December 29).

1) design, synthesis and activity study of a novel six-membered aromatic heterocyclic drug-resistant HIV-1 NNRTI. National Natural Fund, project number: 81273354, project host from January 213 to December 216

2) design, synthesis and activity study of a novel HEPT HIV-1 non-nucleoside reverse transcriptase inhibitor, which is a major international cooperation project of National Natural Fund. 21.1-213.12 Project Moderator 3). Triphenylmedicine International Cooperation Project (Xinhua Pharmaceutical Joint Project), National Major New Drug Creation: Construction of Innovative Drug Incubation Base in Shandong Province, (21ZX941-32-3-1), 21.5-213.5.4). Technical transformation of aspirin raw materials (Xinhua Pharmaceutical Joint Project) The first batch of national major new drug creation "125" project (211 zx923-1-1): May 211-May 214) Design, synthesis and activity research of new drug-resistant HEPT HIV-1 non-nucleoside reverse transcriptase inhibitors. Doctoral program fund of Ministry of Education-priority development field project. Project number: 211131135. From January 211 to December 213, Moderator 6) Design, synthesis and activity study of HIV-1 non-nucleoside reverse transcriptase inhibitors with substituted thiadiazine. Shandong Provincial Natural Fund, ProjectNo.: Zr 29M16 December 29-December 212 Project Moderator.